

BMPR-II Monoclonal Antibody

Catalog No: YM0075

Reactivity: Human; Mouse; Rat; Monkey

Applications: WB;IHC;IF;ELISA

Target: BMPR-II

Fields: >>Cytokine-cytokine receptor interaction;>>TGF-beta signaling

pathway;>>Axon guidance;>>Hippo signaling pathway;>>Signaling pathways regulating pluripotency of stem cells;>>MicroRNAs in cancer;>>Fluid shear stress

and atherosclerosis

Gene Name: BMPR2

Protein Name: Bone morphogenetic protein receptor type-2

Q13873

O35607

Human Gene Id: 659

Human Swiss Prot

No:

Mouse Gene Id: 12168

Mouse Swiss Prot

No:

Immunogen: Purified recombinant fragment of human BMPR-II expressed in E. Coli.

Specificity: BMPR-II Monoclonal Antibody detects endogenous levels of BMPR-II protein.

Formulation : Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Monoclonal, Mouse

Dilution: WB 1:500 - 1:2000. IHC 1:200 - 1:1000. IF 1:200 - 1:1000. ELISA: 1:10000. Not

yet tested in other applications.

Purification : Affinity purification

1/4



Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Molecularweight: 115kD

Cell Pathway: Cytokine-cytokine receptor interaction;TGF-beta;

P References: 1. J Heart Lung Transplant. 2008 Jun;27(6):668-74.

2. Genet Med. 2008 May;10(5):359-65.

Background : This gene encodes a member of the bone morphogenetic protein (BMP)

receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of two different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands

in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension, both familial and fenfluramine-associated, and

with pulmonary venoocclusive disea

Function : catalytic activity:ATP + [receptor-protein] = ADP + [receptor-protein]

phosphate.,cofactor:Magnesium or manganese.,disease:Defects in BMPR2 are a cause of pulmonary venoocclusive disease (PVOD) [MIM:265450]. PVOD is a rare form of pulmonary hypertension in which the vascular changes originate in the small pulmonary veins and venules. The pathogenesis is unknown and any link with PPH1 has been speculative. The finding of PVOD associated with a

BMPR2 mutation reveals a possible pathogenetic connection with PPH1., disease: Defects in BMPR2 are the cause of primary pulmonary

hypertension (PPH1) [MIM:178600]. PPH1 is a rare autosomal dominant disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right

ventricular failure, and death. The disease can occur from infancy throughout life

and i

Subcellular Location : Cell membrane ; Single-pass type I membrane protein.

Expression : Highly expressed in heart and liver.

Sort: 2811


No4: 1

Host: Mouse


2/4

Modifications: Unmodified


Products Images



Western Blot analysis using BMPR-II Monoclonal Antibody against HeLa (1), A431 (2), NIH/3T3 (3), Cos7 (4) and PC-12 (5) cell lysate.



Immunohistochemistry analysis of paraffin-embedded muscle tissues (left) and kidney cancer tissues (right) with DAB staining using BMPR-II Monoclonal Antibody.



Immunofluorescence analysis of Eca109 cells using BMPR-II Monoclonal Antibody (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.

